🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against drug-resistant strains of the pathogen, according to health experts.

An International Health Concern

Cases of gonorrhoea are escalating around the world, with data suggesting more than 82 million instances each year. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely step in the context of growing infection rates, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance found that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Gain Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for drug creation. The charitable organization GARDP collaborated with the drug firm its industry partner to see it through.

“This approval signifies a huge turning point in the management of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Results and Global Access

According to data released by a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This establishes an comparable level with the existing first-line therapy, which uses two antibiotics. The study involved nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors treating patients have shared positive views. Access to a single-dose, oral treatment like this is described as a "critical tool" for managing the epidemic. This is deemed essential to alleviate the strain of the infection for people and to prevent the spread of extremely resistant gonorrhoea worldwide.